Clinical and Experimental Dermatology最新文献

{"title":"Scalp hair repigmentation after radiotherapy.","authors":"Andrew Maxwell, Christopher Yee-Min Chew, Ian Porter, Rodney Sinclair, Adam Sheridan","doi":"10.1093/ced/llaf261","DOIUrl":"https://doi.org/10.1093/ced/llaf261","url":null,"abstract":"<p><p>We report a rare case of scalp hair repigmentation after radiotherapy in a 76-year-old male. The patient had grey scalp hairs for over a decade, and was treated with radiotherapy, 45 Gy delivered over 25 fractions, for squamous cell carcinoma of the scalp and neck. He subsequently underwent a period of radiotherapy-induced alopecia and when his hair regrew four months later it was unexpectedly coloured orange to brown, his natural hair colour in his youth. There are limited reported cases of this phenomenon. This report adds to the limited literature, highlighting the role of hair follicle melanocytes and melanocyte stem cell plasticity in hair colour restoration, and how factors such as radiation may influence it.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective study.","authors":"Francesca Satolli, Silvia Gerosa, Martina Burlando, Emanuele Claudio Cozzani, Claudia Lasagni, Marco Manfredini, Alessandra Narcisi, Angelo Valerio Marzano, Carlo Giovanni Carrera, Matteo Megna, Annalisa Cagni, Maria Esposito, Maria Concetta Fargnoli, Vito Di Lernia, Francesca Peccerillo, Marco Romanelli, Emanuele Trovato, Paolo Amerio, Andrea Carugno, Giovanna Brunasso, Giulia Rech, Riccardo Balestri, Luca Mastorino, Pietro Quaglino, Marco Brusasco, Claudio Feliciani","doi":"10.1093/ced/llaf184","DOIUrl":"https://doi.org/10.1093/ced/llaf184","url":null,"abstract":"<p><strong>Background: </strong>The management of psoriasis in patients with a history of cancer remains debated, especially for the limited literature available. Given the lack of large, well-designed studies focused on this patient group, real-world clinical experiences and expert insights serve as crucial resources for guiding informed treatment decisions. This issue particularly regards the newest anti-interleukin (IL) drugs available, such as those targeting IL-23.</p><p><strong>Objectives: </strong>To analyse a real-world population of patients with psoriasis undergoing biologic treatment with anti-IL-23 drugs who also have a concurrent cancer diagnosis.</p><p><strong>Methods: </strong>A retrospective, observational, multicentre study was conducted, enrolling adult patients with moderate-to-severe plaque psoriasis and a personal history of malignancy. The patients were undergoing any anti-IL-23 treatment approved for psoriasis (guselkumab, risankizumab or tildrakizumab).</p><p><strong>Results: </strong>In total, 198 patients were enrolled. Among these, 67 (33.8%) had a history of malignancy within the past 5 years, whereas 131 (66.2%) had been diagnosed with cancer prior to that time. During the period of the study, six patients (3.0%) experienced progression or recurrence of their existing neoplasia. Moreover, six (3.0%) were diagnosed with a new neoplasia during the study period, discontinuing biologic treatment in only two cases. A subanalysis investigating the relationship between comorbidities and the incidence of neoplastic progression or recurrence during therapy, as well as the development of a new neoplasia, did not show any statistically significant associations. Similarly, significant associations between previous treatments and increased risk of cancer recurrence, progression or development were not found.</p><p><strong>Conclusions: </strong>Our real-life experience is the largest study investigating the use of anti-IL-23 agents and the risk of cancer recurrence, progression and development in patients with a history of cancer. This study confirms their safety also in this cohort of patients.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin surgery and cosmetic dermatology.","authors":"Eimear Duff, Roisin Rynne, Cliona Feighery, Niamh Kearney","doi":"10.1093/ced/llaf251","DOIUrl":"https://doi.org/10.1093/ced/llaf251","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All pain, no gain: Porokeratosis ptychotropica remains a therapeutic challenge.","authors":"Sophie Bashall, Sarah Ryan, Justin Hau, Natalie Attard, Nastassia Nardini, Zidan Anoud, Natalia Castrejon DeAnta, David Chandler, Marieta Papanikolaou","doi":"10.1093/ced/llaf242","DOIUrl":"https://doi.org/10.1093/ced/llaf242","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic Dermatitis and Obsessive-Compulsive Disorder: A Systematic Review.","authors":"Sheila Sharifi, Isabella J Tan, Mohammad Jafferany","doi":"10.1093/ced/llaf259","DOIUrl":"https://doi.org/10.1093/ced/llaf259","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a prominent inflammatory skin disorder that significantly affects daily functioning and mental health in patients. Among its psychological repercussions, besides anxiety and depression, obsessive-compulsive disorder (OCD) has emerged with multiple studies indicating an increased risk of OCD in AD patients. This systematic review aims to synthesize and evaluate the current literature on the association between AD and OCD, with particular attention to mechanisms linking disease and integrative treatment approaches. A search of the PubMed, PsycINFO, and Web of Science databases was performed on September 12, 2024 to select peer-reviewed English studies relevant to our topic. Our results revealed the influences of demographic variables such as gender, age, and atopic severity as central to concomitant disease prevalence, with women and young adults posing the highest risk of comorbidity. The complex interaction between the two disease states is thought to be a bidirectional relationship characterized by immunological, behavioral, and genetic factors. Hence, an understanding of underlying pathophysiology is necessary for comprehensive management. Patients may benefit from a multifaceted approach including prescription of immunomodulatory agents and referral to psychiatry and psychology. Ultimately, we seek to inform clinical practice by advocating for interdisciplinary approaches to care and providing the framework for future investigations.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose modulation strategies in psoriatic patients: real-world comparison between secukinumab and brodalumab for up to one year after dose spacing.","authors":"Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Yingying Liao, Margherita Pelucchi, Francesco Leo, Pietro Quaglino, Simone Ribero","doi":"10.1093/ced/llaf250","DOIUrl":"https://doi.org/10.1093/ced/llaf250","url":null,"abstract":"<p><strong>Introduction: </strong>Modulation of the regimen of biologics, including dose reduction (de-escalation) and dose augmentation (escalation), is of increasing interest in psoriatic patients.De-escalation strategies include reducing the single therapeutic dose, the mg/kg ratio or number of injections, and dose-spacing (D-S), i.e. extending the interval between administrations. Real-life data regarding dose de-escalation are lacking.</p><p><strong>Objectives: </strong>We aim to retrospectively analyse the effectiveness and drug survival of D-S of secukinumab and brodalumab in a real-world setting.</p><p><strong>Materials and methods: </strong>This is a cohort study with a retrospective analysis of the general characteristics and effectiveness of patients with psoriasis undergoing therapeutic biologic D-S with secukinumab or brodalumab.</p><p><strong>Results: </strong>Eighty patients, 38.75% treated with secukinumab and 61.25% treated with brodalumab, underwent dose modulation by D-S of 50% of the approved range. After a mean of 35 months the population underwent D-S. At D-S, the mean PASI was 0.1, ranging from 0.7 to 0.1 in the following year. PASI100 was achieved by 91% at the date of D-S, and remained stable over the following year. Similar trends were seen for PASI 90 and PASI≤1 with 99%, and 100% of achievement at the time of D-S, which were maintained at 12 months post-D-S. The 12-month drug survival of the D-S regimen was 66%, with 1 in 4 patients returning to standard dosage, and PASI 100 was regained in two-third of these cases. Secukinumab showed a drug survival after D-S of 78.3% vs 58.9% of brodalumab. No differences in mean and relative PASIs at any time point after D-S were found between the two treatments.</p><p><strong>Conclusions: </strong>Therapeutic modulation of IL-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to one year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of the Cost and Carbon Footprint of Acne Treatments in the NHS.","authors":"Sarika Grover, William Hunt, Rachel A Abbott, David de Berker, Tamara Griffiths, Dennis Niebel, Simon Tso","doi":"10.1093/ced/llaf258","DOIUrl":"https://doi.org/10.1093/ced/llaf258","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granulomatous reaction to red tattoo pigment successfully treated with topical allopurinol.","authors":"Marcial Álvarez-Salafranca, Itziar Muelas-Rives, Iranzu Barandika-Urrutia, Ignacio Hernández-Aragües, María Carmen Gómez-Mateo","doi":"10.1093/ced/llaf257","DOIUrl":"https://doi.org/10.1093/ced/llaf257","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hidradenitis suppurativa in pediatric patients with Down Syndrome: a comparative study of 116 cases and controls.","authors":"Maria Sin-Soler, Magdalini Louka, Patricia Garbayo-Salmons, Antonio Torrelo, Angela Hernández-Martín, Lucero Noguera-Morel","doi":"10.1093/ced/llaf256","DOIUrl":"https://doi.org/10.1093/ced/llaf256","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) seems to be more prevalent in patients with Down syndrome (DS), with earlier onset, higher incidence in females, and increased body mass index (BMI) in these individuals.</p><p><strong>Objectives: </strong>To describe the demographic, clinical characteristics, and severity of HS in children with DS and compare them to DS-non-HS patients.</p><p><strong>Methods: </strong>A retrospective, observational, 5-year study of children (<18 years) with DS at Hospital Infantil Universitario Niño Jesús.</p><p><strong>Results: </strong>HS was diagnosed in 32 of 116 DS patients. The median age at onset was 13 years, with 53.1% female, and a median BMI of 24.4kg/m². The most common phenotype was follicular (46.9%), and the majority (84.4%) had mild disease (Hurley I). The groin (75%) and buttocks (65.6%) were the most affected areas. Treatment mainly involved topical and oral antibiotics, with 9.4% undergoing surgery. Significant differences were observed across phenotypes in sex distribution, HS lesion location, and surgical rates. Compared to DS-non-HS patients, our data report higher BMI, and greater association with the follicular occlusion tetrad. The limitations of this study include its retrospective nature, small sample size, and data collected from a single center.</p><p><strong>Conclusions: </strong>HS in children with DS is characterized by an early onset, higher BMI, predominance of follicular phenotype, and mild severity.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study.","authors":"Francesca Barei, Alessandra Chiei-Gallo, Alessandra Narcisi, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Giampiero Girolomoni, Martina Maurelli, Elena Pezzolo, Claudio Sciarrone, Massimo Gola, Manfredi Magliulo, Paola Savoia, Elia Esposto, Anna G Burroni, Fabrizio Amoruso, Vittoria Giulia Bianchi, Santo R Mercuri, Francesca Satolli, Maria Beatrice De Felici Del Giudice, Paolo Pella, Roberto Pinto, Gianluca Avallone, Carlotta Gurioli, Bianca Maria Piraccini, Anna Balato, Eugenia V Di Brizzi, Rosa Giuseppa Angileri, Flavia Manzo Margiotta, Marco Romanelli, Mariateresa Rossi, Mario Bruno Guanti, Giuseppe Lauretta, Stefano Dastoli, Cataldo Patruno, Maddalena Napolitano, Michela Ortoncelli, Simone Ribero, Angelo V Marzano, Silvia Ferrucci","doi":"10.1093/ced/llaf253","DOIUrl":"https://doi.org/10.1093/ced/llaf253","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world data comparing patients with atopic dermatitis (AD) initially treated with upadacitinib versus those previously treated with biologics or other JAK inhibitors are limited.</p><p><strong>Methods: </strong>We conducted a retrospective multicenter study of 524 patients with moderate-to-severe AD treated with upadacitinib to assess clinical outcomes over 52 weeks. A sub-analysis of 316 patients compared outcomes between those who had previously failed Th2 biologics (group A) and those who discontinued these treatments for reasons other than inefficacy or were bio-naïve (group B), using a Propensity Score matching method.</p><p><strong>Results: </strong>A significant clinical improvement starting from week 4 and continuing throughout the study period was observed in the overall population and both in group A and B. Group B showed greater improvements at later follow-up times, with a higher median EASI (Eczema Area and Severity Index) percentage improvement at week 52 (p=0.030), a significantly higher proportion of patients achieving EASI-90 and EASI-100 at week 36 (p=0.023, χ²=9.497). As for the P-NRS (Pruritus Numerical Rating Scale) and SD-NRS (Sleep Distrubances Numerical Rating Scale), group B had a significantly greater percentage of patients reporting a score of 0 or 1 at week 52 (P-NRS: p=0.017, χ²=5.665; SD-NRS: p=0.049, χ²=3.870). Group B also had a significantly higher percentage of patients reaching minimal disease activiy at week 52 (p=0.014, χ²=5.980).</p><p><strong>Conclusion: </strong>Upadacitinib proved to be effective in the long term not only as a first-line therapy but also in patients with a history of biologic treatment failure. However, patients in Group B consistently demonstrated better clinical responses at later follow-ups, suggesting that bio-naïve individuals and those who discontinued Th2 biologics for reasons other than inefficacy may respond more favorably to upadacitinib.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}